NCT00613132: Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG |
|
|
| Completed | 1 | 78 | US | Gleevec, RAD001, and Hydroxyurea, Gleevec-Imatinib-Imatinib mesylate, RAD001-Everolimus, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide | Annick Desjardins, Novartis Pharmaceuticals | Glioblastoma, Gliosarcoma | 08/08 | 01/13 | | |
NCT00613054: Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma |
|
|
| Completed | 1 | 27 | US | Zactima, Gleevec, Hydroxyurea, Zactima-ZD6474-Vandetanib, Gleevec-Imatinib mesylate, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide | Annick Desjardins, Novartis Pharmaceuticals, AstraZeneca | Glioblastoma, Gliosarcoma | 03/09 | 04/09 | | |
